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Abstract
Background: Current practice guidelines offer different management recommendations for adults
presenting with a sore throat. The key issue is the extent to which the clinical likelihood of a Group
A streptococcal infection should affect patient management decisions. To help resolve this issue,
we conducted a multi-criteria decision analysis using the Analytic Hierarchy Process.
Methods:  We defined optimal patient management using four criteria: 1) reduce symptom
duration; 2) prevent infectious complications, local and systemic; 3) minimize antibiotic side effects,
minor and anaphylaxis; and 4) achieve prudent use of antibiotics, avoiding both over-use and under-
use. In our baseline analysis we assumed that all criteria and sub-criteria were equally important
except minimizing anaphylactic side effects, which was judged very strongly more important than
minimizing minor side effects. Management strategies included: a) No test, No treatment; b)
Perform a rapid strep test and treat if positive; c) Perform a throat culture and treat if positive; d)
Perform a rapid strep test and treat if positive; if negative obtain a throat culture and treat if
positive; and e) treat without further tests. We defined four scenarios based on the likelihood of
group A streptococcal infection using the Centor score, a well-validated clinical index. Published
data were used to estimate the likelihoods of clinical outcomes and the test operating
characteristics of the rapid strep test and throat culture for identifying group A streptococcal
infections.
Results: Using the baseline assumptions, no testing and no treatment is preferred for patients with
Centor scores of 1; two strategies – culture and treat if positive and rapid strep with culture of
negative results – are equally preferable for patients with Centor scores of 2; and rapid strep with
culture of negative results is the best management strategy for patients with Centor scores 3 or 4.
These results are sensitive to the priorities assigned to the decision criteria, especially avoiding
over-use versus under-use of antibiotics, and the population prevalence of Group A streptococcal
pharyngitis.
Conclusion: The optimal clinical management of adults with sore throat depends on both the
clinical probability of a group A streptococcal infection and clinical judgments that incorporate
individual patient and practice circumstances.
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Background
Sore throat is one of the most common illnesses for which
patients consult their physicians in the United States with
an estimated 6.7 million adult visits to primary care pro-
viders each year; nearly three-quarters of these visits result
in antibiotic prescriptions [1,2]. The Group A streptococ-
cus is the most common bacterial cause of acute pharyn-
gitis, accounting for 5–26% cases in adults. Higher rates
occur in emergency room and urgent care settings and
during the winter and early spring [3-5].
A well-validated clinical algorithm for estimating the like-
lihood of a Group A streptococcal infection in a patient
presenting with a sore throat called the Centor Score is
available [6]. The Centor score is calculated by determin-
ing how many of the following four clinical features are
present: history of fever, tonsillar exudates, anterior cervi-
cal adenopathy, and absence of cough. In a variety of
adult populations, the prevalence of Group A streptococ-
cal infections has been shown to be proportional to the
Centor score. For example, when the population preva-
lence is 10%, the likelihood of a Group A streptococcal
infection ranges from 3% if one feature is present to 41%
when all four exist [3].
Despite the existence of this clinical prediction rule and
extensive medical literature on this topic, conflicting
approaches to the diagnosis and management of sore-
throat are currently proposed in guidelines issued by the
Infectious Diseases Society of America (IDSA) on one
hand [7], and American College of Physicians (ACP), in
collaboration with the Centers for Disease Control and
the American Academy of Family Physicians [8,9], on the
other. Both guidelines identify the major issue in sore
throat management as the identification of patients with
Group A streptococcal infections for whom antibiotic
treatment is indicated, but they differ in the usefulness
they ascribe to the clinical estimation of the likelihood
Group A streptococcal infection in making management
decisions. Both guidelines agree that no testing or treat-
ment is appropriate for patients with a low likelihood of
Group A Streptococcal pharyngitis, based on a Centor
score of 1. The differences occur in management recom-
mendations for patients with Centor scores 2 and above.
The decision model Figure 1
The decision model. Please refer to the text for definitions of the decision criteria and sub-criteria on middle two levels and 
the management alternatives on the bottom level.
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The IDSA recommends laboratory confirmation of a
Group A streptococcal infection in all cases whereas the
ACP guideline endorses several management options,
including empiric treatment, for patients with Centor
scores of 3 and 4.
To help clinicians better understand the differences
between these two conflicting guidelines and decide
which one they should follow, we conducted a multi-cri-
teria decision analysis using the Analytic Hierarchy Proc-
ess (AHP).
Methods
The Analytic Hierarchy Process (AHP) is one of several
multi-criteria decision analysis methods designed to help
people make better decisions in complex situations
involving tradeoffs between the advantages and disadvan-
tages of several alternatives [10]. An AHP analysis can be
divided into five steps.
The first step consists of defining the goal of the decision,
the alternatives being considered, and the criteria that will
be used to determine how well the alternatives can be
expected to meet the goal. In addition, different decision
perspectives and/or scenarios can be defined. These deci-
sion elements are then organized into a hierarchical deci-
sion model with the goal at the top, the alternatives at the
bottom, and the criteria in between. The model serves as
both a description of the decision problem and a frame-
work for dividing the decision into smaller, more manage-
able components for subsequent analysis.
In the second step of an AHP analysis, information about
how well the alternatives can be expected to fulfil the deci-
sion criteria is gathered and summarized.
The third step consists of comparing the alternatives' abil-
ities to fulfil the criteria and judging the importance of the
criteria relative to the goal of the decision. If the model
includes different decision perspectives or scenarios, sep-
arate judgements are made for each. The recommended
format for making all of these judgements is a series of
pairwise comparisons between two elements at a time.
After all the comparisons are made they are combined to
create a normalized, ratio scale that summarizes the
results of the direct and indirect comparisons made
among the decision elements. The internal consistency of
the judgements within a set of pairwise comparisons is
routinely assessed using a measure called the consistency
ratio. A consistency ratio of 0 indicates perfect consist-
Results of baseline analysis Figure 2
Results of baseline analysis.
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ency. By convention, consistency ratios less than 0.1 are
considered acceptable.
In the fourth step of the AHP, the scales created in step 3
are combined to create a summary score indicating how
well the alternatives can be expected to meet the goal. This
is done in a manner that is analogous to calculating a
weighted average by multiplying the scores indicating
how well alternatives fulfil the criteria by the priorities
assigned to the criteria and adding the results. The result-
ing scores, which add up to one and are commonly
expressed as percentages, indicate the alternatives' relative
abilities to fulfil the goal of the decision.
The fifth step consists of sensitivity analyses to explore the
effects of changing the data or judgements used in the
original analysis.
These steps, as they were carried out in the conduct of this
analysis, are illustrated below. More detailed descriptions
of the AHP have been published previously [11-13].
Sore throat management analysis step one
We performed the analysis from the perspective of a pri-
mary care practitioner in an office setting seeing an adult
patient aged 18 years or older with a chief complaint of
sore throat. The goal was to identify optimal office man-
agement of such a patient. We defined four criteria for
determining optimal management: 1) To shorten the
duration of illness; 2) To prevent infectious complica-
tions; 3) To minimize antibiotic side effects; and 4) Opti-
mal antibiotic use. The criterion preventing infectious
complications was broken down into two sub-criteria:
prevent local complications (peri-tonsillar abscess) and
prevent systemic complications (acute rheumatic fever).
Avoid antibiotic side effects was divided into minor (rash,
gastrointestinal distress) and major (anaphylaxis). Opti-
mal antibiotic use was divided into avoiding under-treat-
ment with antibiotics to reduce the chance of potentially
preventable spread of disease to household and other
contacts and avoiding over-treatment to reduce unneces-
sary antibiotic use and the development of bacterial anti-
biotic resistance.
Results by criteria, Group 1 baseline analysis Figure 3
Results by criteria, Group 1 baseline analysis.
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We examined five potential management strategies:
• No testing and no treatment (NO TEST, NO TREAT);
• Obtain a rapid streptococcal antigen test and treat
patients who test positive, do not treat patients who test
negative (RAPID STREP);
• Obtain a throat culture and treat patients who test posi-
tive, do not treat if negative (CULTURE);
• Obtain a rapid streptococcal antigen test and treat
patients who test positive. Obtain a throat culture on
patients who test negative and treat if the culture is posi-
tive (RAPID STREP & CULTURE);
• Treat everyone with no further diagnostic testing.
(EMPIRIC TREATMENT).
To examine the effects of different likelihoods of Group A
streptococcal pharyngitis, we created four clinical scenar-
ios, one for each of the four possible Centor score results.
To make our analysis comparable with earlier studies, we
assumed a population prevalence of Group A streptococ-
cal pharyngitis of 10% and, based on published data in
adult patients coming to the primary care office in the US,
used the following estimates for the prevalence of Group
A Streptococcal pharyngitis in each scenario: 3% for Cen-
tor score 1, 8% for Centor score 2, 19% for Centor score
3, and 41% for Centor score 4 [3,5]. The resulting decision
model is shown in Figure 1. The effects of increasing the
population prevalence to 20% were explored in a sensitiv-
ity analysis, described below.
Step two – assemble and organize outcome information
To simplify the analysis, we limited it to patients who are
not known to be allergic to penicillin. We assumed that all
untreated episodes of pharyngitis, bacterial or non-bacte-
rial, produce five days of symptoms [14] and that patients
are being seen within three days of symptom onset. We
also assumed that all treated patients would receive a 10-
day course of oral penicillin therapy and that penicillin
provides two days of symptom improvement if begun
immediately and one day of improvement if delayed 24
hours while awaiting culture results [15]. We estimated
the mean duration of symptoms for each management
option using Bayes's theorem, the prevalence of Group A
streptococcal infections, and the test operating character-
Results by criteria, Group 2 baseline analysis Figure 4
Results by criteria, Group 2 baseline analysis.
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istics of rapid streptococcal antigen tests and throat cul-
tures to calculate the number of patients in each scenario
with true and false positive and negative test results. The
data used to perform these calculations are summarized in
Table 1[5,16]. We then determined the number of
patients per thousand in each scenario with Group A
streptococcal pharyngitis who would be treated and
reduced their symptom duration based on when their
treatment would begin under each management option.
The total number of symptomatic days for the entire
cohort was then calculated and divided by 1,000 to derive
the mean duration of illness.
The likelihoods of the other outcomes were estimated in
a similar way. The risks of local and systemic complica-
tions were based on the prevalence of patients in each
option with treated and untreated Group A streptococcal
infections and the estimated likelihoods of complications
in each group. We calculated the chances of antibiotic side
effects by multiplying the proportion of patients in each
management group who would be treated with penicillin
times their estimated risk of side effects [5,15,17]. The
likelihood of over-treatment with antibiotics associated
with each management strategy was determined by calcu-
lating the likelihood that patients without Group A strep-
tococcal infections would be treated. We determined
under-treatment with antibiotics by calculating the likeli-
hood that patients with Group A streptococcal infections
would not be treated under each management strategy.
The resulting outcome estimates associated with the alter-
native management strategies for each clinical scenario
are summarized in Additional file 1 [see Additional file 1].
To facilitate comparisons among the outcomes, similar
results were grouped into categories that are also included
in Additional file 1 [see Additional file 1].
Step three – make comparisons
a) Comparisons among alternatives relative to the criteria
We compared the management strategies' abilities to
shorten the duration of illness by dividing the reciprocals
of the mean duration of illness associated with each strat-
egy (since a shorter duration of illness is preferable).
Comparisons among the alternatives with regard to the
other criteria were made using standard AHP pairwise
comparisons among the outcome categories defined in
the previous step. Because of the large number of out-
comes that are possible if all four Centor groups are com-
bined, these comparisons were made separately for each
Results by criteria, Group 3 baseline analysis Figure 5
Results by criteria, Group 3 baseline analysis.
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Centor group. Detailed information about these compar-
isons is included in Additional file 2 [see Additional file
2].
b) Comparisons among the criteria
In the baseline analysis we assumed that all criteria and
sub-criteria are equally important in making a manage-
ment decision with one exception: in terms of avoiding
penicillin side effects, we judged avoiding an anaphylactic
reaction very strongly more important than avoiding a
minor reaction such as a skin rash. We explored how dif-
ferent judgments regarding the priorities of the criteria
affected the results in a series of sensitivity analyses, fur-
ther described below.
Step four – combine all judgments to determine how well 
alternatives can be expected to meet the goal
We used the standard AHP weighted averaging method to
combine the results of the judgments made in step three
to determine the relative abilities of the management
options to meet the goal for each of the four clinical sce-
narios. We defined relative differences between options of
≥ 1.1 as significant.
Step five – sensitivity analysis
We explored the impact of different judgments regarding
the relative importance of the criteria and sub-criteria by
varying their priorities from 0 (of no importance) to 1
(the only consideration that is important) and recalculat-
ing the alternatives' overall scores. We also repeated the
baseline analysis assuming that the prevalence of Group A
streptococcal infections was 20%. The data used for this
analysis are summarized in Additional file 3 [see Addi-
tional file 3]. Details about the pairwise comparisons
among the outcome estimates used for this analysis are
contained in Additional file 4 [see Additional file 4].
All AHP analyses were conducting using Expert Choice
2000, a standard AHP software program [18].
Results
Baseline analysis
The results of the baseline analysis are summarized in Fig-
ure 2. The most preferred strategies are NO TEST, NO
TREAT for patients with a Centor score of 1, CULTURE or
RAPID STREP & CULTURE for patients with a Centor
score of 2, and RAPID STREP & CULTURE for patients
with Centor scores of 3 or 4.
Results by criteria, Group 4 baseline analysis Figure 6
Results by criteria, Group 4 baseline analysis.
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For patients with Centor scores of 1, NO TEST, NO TREAT
has the highest priority score, 21.8%. This score is 1.02
times better than CULTURE (priority score 21.3%), 1.11
times better than RAPID STREP & CULTURE, 1.12 times
better than RAPID STREP, and 1.22 times better than
EMPIRIC TREATMENT. Figure 3 illustrates the strengths
and weaknesses of the management strategies in this situ-
ation. NO TEST, NO TREAT is the best option in terms of
avoiding antibiotic side effects and optimal antibiotic use.
These advantages more than compensate for its relatively
weak performance in preventing infectious complica-
tions.
In patients with a Centor score of 2, CULTURE and RAPID
STREP & CULTURE are tied for most preferred strategy
with priority scores of 20.9% and 20.8% respectively.
These two options are 1.03 times better than NO TEST NO
TREAT (priority score 20.2%), 1.06 times better than
RAPID STREP (priority score 19.7%), and 1.14 times bet-
ter than EMPIRIC TREATMENT (priority score 18.4%).
Figure 4 shows that this is because these two strategies are
substantially better than EMPIRIC TREATMENT and
RAPID STREP in terms of optimal antibiotic use and bet-
ter than NO TEST, NO TREAT in preventing complica-
tions.
For patients with a Centor score of 3, the preferred strategy
is RAPID STREP & CULTURE, priority score 21%. This
option is 1.02 times better than CULTURE (priority score
20.5%), 1.04 times better than NO TEST, NO TREAT (pri-
ority score 20.2%), 1.06 times better than EMPIRIC
TREATMENT (priority score 19.8%), and 1.13 times better
than RAPID STREP (priority score 18.6%). Figure 5 illus-
trates that, in this group, RAPID STREP & CULTURE is the
best strategy for preventing complications, optimizing
antibiotic use, and shortening the duration of symptoms.
For patients with a Centor score of 4, RAPID STREP &
CULTURE is again the best management strategy with a
priority score 22.0%. It is 1.06 times better than EMPIRIC
TREATMENT (priority score 20.7%), 1.12 times better
than CULTURE (priority score 19.6%), 1.16 times better
One-way sensitivity analysis, priorities of avoid over-use versus under-use of antibiotics for Centor Group 3 patients Figure 7
One-way sensitivity analysis, priorities of avoid over-use versus under-use of antibiotics for Centor Group 3 patients.
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than RAPID STREP (priority score 18.9%) and 1.17 times
better than NO TEST, NO TREAT (priority score 18.8%).
As shown in Figure 6, the main advantage of RAPID
STREP & CULTURE in this situation is its ability to both
prevent complications and promote optimal antibiotic
use.
Sensitivity analyses
In the decision model, there are 28 possible changes in the
relative priorities assigned to the decision criteria and sub-
criteria. The sensitivity analysis revealed that 14 of these
changes resulted in a change in preferred management
strategy from the one(s) identified using the baseline
assumptions. These results are summarized in Table 2.
Changes in preferred management strategy were associ-
ated with alterations in the priorities of all criteria except
preventing local versus systemic infectious complications.
The most changes were associated with differences in the
relative priorities of avoiding over-use versus under-use of
antibiotics, which was the only criterion that affected the
results of all four Centor groups. These results are illus-
trated in Figure 7, which shows the effects of varying the
priorities assigned to these two sub-criteria relative to
their parent criterion, Optimal antibiotic use, for Centor
group 3. EMPIRIC TREATMENT is the most preferred
management strategy when the priority of avoid over-use
of antibiotics is between 0 and 26.4%. RAPID STREP &
CULTURE is preferred when the priority of avoid over-use
is between 26.5% and 56.5%; this interval includes the
baseline value of 50%. For higher priorities, NO TEST, NO
TREAT is preferred. Similar "double-thresholds" also
occurred in Centor groups 2 and 4. Additional graphs
illustrating these one-way sensitivity analysis results are
included in Additional file 5 [see Additional file 5].
The results of increasing the population prevalence of
Group A streptococcal pharyngitis from 10% to 20% in
the baseline analysis are illustrated in Figure 8. CULTURE
becomes the preferred strategy for patients with Centor
Sensitivity analysis, 20% population prevalence of Group A streptococcal pharyngitis Figure 8
Sensitivity analysis, 20% population prevalence of Group A streptococcal pharyngitis.
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scores of 1 or 2 whereas RAPID STREP & CULTURE
remains the preferred strategy for patients with Centor
scores 3 or 4.
Discussion
Because of its frequency, optimal management of patients
presenting with a sore throat is an important quality of
care issue in ambulatory settings. The best way to manage
an adult patient with a sore throat, however, has been
hard to determine. Different management strategies have
been advocated, even within the same institution [19].
Ironically, the uncertainty about appropriate manage-
ment was heightened, not lessened, by the recent publica-
tion of two clinical guidelines that make different patient
management recommendations [7,9].
The results of our analysis help explain why it is so diffi-
cult to identify the best way to manage this common clin-
ical problem and provide guidance for clinicians seeking
to identify the optimal approach to managing adult
patients with sore throats. As illustrated by the baseline
analysis, there is no clearly superior patient management
strategy. In almost every scenario, as illustrated by the
small differences in priority scores, there are at least two or
three management strategies that are very similar in their
abilities to meet all of the decision criteria. The sensitivity
analyses show that the choice of management strategy
depends on the relative priorities assigned to the criteria
being used to evaluate the alternatives and the clinical
likelihood of Group A streptococcal pharyngitis. The most
important judgment among the criteria is the relative pri-
ority of avoiding over-use of antibiotics, which is impor-
tant to reduce the development of bacterial resistance to
antibiotics, versus avoiding under-use, which is important
to prevent the spread of infection to household members
and other close contacts. Although mentioned as a con-
sideration in both the IDSA and ACP guidelines, neither
identifies reducing the spread of infection as a major fac-
tor in making treatment decisions. This result suggests
that the importance of reducing the spread of infection in
making treatment decisions may have been underesti-
mated in both sets of guidelines.
These findings suggest that differences in decision criteria
and/or the priorities assigned to them account for some, if
not all, of the discrepancies in current recommendations
regarding the management of adult patients with a sore
throat. They further suggest that it may not be possible to
define a universally preferred management strategy, mak-
ing this clinical problem unsuitable for traditionally for-
mulated clinical guidelines. Rather, it may be necessary to
develop and implement a flexible guideline approach that
combines current clinical evidence, including the popula-
tion prevalence of Group A streptococcal pharyngitis, with
the preferences of the individuals involved in clinical
management decisions [20].
The results of our analysis are consistent with those of
McIsaac and colleagues who compared the management
strategies proposed in the same two guidelines in a popu-
lation of patients with sore throats presenting with a Cen-
tor score of 2 or more who had both rapid strep tests and
throat cultures performed [21]. Using throat culture as the
reference standard for diagnosing a group A streptococcal
infection, they found that the best management strategies
were to either culture everyone and only treat patients
with positive results or to culture patients with Centor
scores of 2 or 3 and empirically treat those with a score of
4. They concluded, however, that the optimal manage-
ment of patients with sore throat depends on trade-offs
among the priorities assigned to multiple decision criteria
including identifying a group A streptococcal infection,
Table 1: Data estimates used for the analysis
Baseline assumptions Reference
Prevalence of Group A Streptococcal infection based on population prevalence of 10% and Centor Score Score = 1 3% 3
Score = 2 8 %
Score = 3 19%
Score = 4 41%
Sensitivity of rapid streptococcal antigen test 84% 16
Specificity of rapid streptococcal antigen test 93% 16
Sensitivity of throat culture 78% 16
Specificity of throat culture 99% 16
Risk of penicillin rash 2% 17
Risk of anaphylaxis from oral penicillin 1/10,000 17
Risk of rheumatic fever if untreated 5/10,000 5, 15
Risk of rheumatic fever if treated 15/100,000 5, 15
Risk of peri-tonsillar abscess, if untreated 24/1,000 5, 15
Risk of peri-tonsillar abscess if treated 4/1,000 5, 15BMC Medical Informatics and Decision Making 2006, 6:14 http://www.biomedcentral.com/1472-6947/6/14
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avoiding over-use of antibiotics, the burden of office-
based testing, the value of immediate test results, and the
need for telephone follow-up of throat culture results.
Our results are also compatible with those of Neuner and
colleagues who compared the same management strate-
gies using cost-effectiveness analysis [5]. They found that,
unless the prevalence of group A streptococcal infections
is greater than 70%, all strategies except empiric treatment
were reasonable and cost-effective.
Our study differs from these two previous ones in several
ways. First, both assumed that the throat culture is 100%
sensitive and specific. Although the throat culture is used
as a diagnostic standard in practice, there is good evidence
that it is not a perfect diagnostic test for group A strepto-
coccal pharyngitis in clinical settings due to variations in
culture techniques and the presence of asymptomatic car-
riers [16]. For this reason we used lower values for the sen-
sitivity and specificity of the throat culture to more closely
represent the operating characteristics of this test in rou-
tine practice settings.
The other major difference is that multi-criteria method of
analysis we used provides a way to examine the how
trade-offs among different management objectives affect
the choice of management strategy that is not possible
with standard methods of cost-effectiveness analysis.
This analysis has several limitations. It was limited to
patients in office settings who can be treated with penicil-
lin and it is possible that the results could be different if
other treatment settings or regimens were considered. We
also used literature-derived estimates for the sensitivity
and specificity of the rapid strep tests and throat cultures,
the effect of antibiotic treatment on duration of illness,
and the prevalence of Group A streptococcal infections
that could be inaccurate. A third limitation is that, in
keeping with current guidelines, we assumed that non-
group A streptococcal organisms do not merit antibiotic
treatment. There is evidence, however, that patient out-
comes may be improved if non-group A streptococcal
organisms, especially group C, are treated [22]. We also
did not specifically include the considerations about
office efficiency and the value of immediate microbiologic
results that were identified by McIsaac and colleagues as
potentially important factors in determining patient man-
agement in busy office settings [21]. Finally, because we
chose to compare the outcomes of each clinical scenario
separately, it is not possible to directly compare the prior-
ity scores across the different scenarios.
Table 2: Results of one-way sensitivity analysis
Group Criterion Baseline 
priority
Preferred option, 
baseline
Threshold value(s)
1 Prevent complications 0.25 NO TEST, NO TREAT NO TEST, NO TREAT < 0.406 < RAPID STREP & 
CULTURE or CULTURE
1 Avoid over- vs under use of antibiotics 0.5 NO TEST, NO TREAT CULTURE or RAPID STREP & CULTURE < 0.375 
< NO TEST, NO TREAT
2 Prevent complications 0.25 CULTURE NO TEST, NO TREAT < 0.162 < CULTURE < 
0.429 < RAPID STREP & CULTURE
2 Avoid side effects 0.25 CULTURE CULTURE < 0.457 < NO TEST, NO TREAT
2 Optimal antibiotic use 0.25 CULTURE RAPID STREP & CULTURE < 0.133 < CULTURE 
< 0.619 < NO TEST, NO TREAT
2 Avoid over- vs under use of antibiotics 0.5 CULTURE RAPID STREP & CULTURE < 0.455 < CULTURE 
< 0.674 < NO TEST, NO TREAT
3 Prevent complications 0.25 RAPID STREP & 
CULTURE
NO TEST, NO TREAT < 0.15 < RAPID STREP & 
CULTURE
3 Avoid side effects 0.25 RAPID STREP & 
CULTURE
RAPID STREP & CULTURE < 0.354 < NO TEST, 
NO TREAT
3 Optimal antibiotic use 0.25 RAPID STREP & 
CULTURE
RAPID STREP & CULTURE < 0.389 < CULTURE
3 Avoid over- vs under use of antibiotics 0.5 RAPID STREP & 
CULTURE
EMPIRIC TREATMENT < 0.264 < RAPID STREP 
& CULTURE < 0.565 < NO TEST, NO TREAT
3 Minor penicillin side effect vs anaphylaxis 0.125 RAPID STREP & 
CULTURE
RAPID STREP & CULTURE < 0.44 < NO TEST, 
NO TREAT
4 Avoid treatment side effects 0.25 RAPID STREP & 
CULTURE
RAPID STREP & CULTURE < 0.545 < NO TEST, 
NO TREAT
4 Shorten duration of illness 0.25 RAPID STREP & 
CULTURE
RAPID STREP & CULTURE < 0.864 < CULTURE
4 Avoid over- vs under use of antibiotics 0.5 RAPID STREP & 
CULTURE
EMPIRIC TREATMENT < 0.264 < RAPID STREP 
& CULTURE < 0.737 < NO TEST, NO TREATBMC Medical Informatics and Decision Making 2006, 6:14 http://www.biomedcentral.com/1472-6947/6/14
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Conclusion
In summary, we found that optimal management of adult
patients presenting with a sore throat depends on both
the clinical likelihood of a group A streptococcal infection
and the relative importance assigned to the criteria used to
define good patient management, especially avoiding
over-use versus under-use of antibiotics and preventing
infectious complications. These findings suggest that deci-
sions about management of adults with sore throat
should incorporate both clinical estimates of the likeli-
hood of a group A streptococcal infection and the priori-
ties assigned to pertinent decision criteria by those
affected by the decision. The results of this analysis pro-
vide an initial basis for determining the patient manage-
ment implications of different priority judgments.
Additional research is needed to more firmly establish the
set of criteria that should be used to define quality man-
agement of adults presenting to primary care settings with
sore throats and to assess the range of priorities patients,
primary care practitioners and other interested parties
assign to them. Until these results are available, we suggest
that clinicians establish the likelihood of a Group A strep-
tococcal infection using the Centor score and clinical set-
ting, assess the relative priorities of avoid under-use versus
over-use of antibiotics based on each patient's preferences
and circumstances, and use the sensitivity analysis results
presented in Table 2 to guide their patient management
decisions.
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